Medlab Clinical Limited (ASX:MDC) shares rose 2.7% on Tuesday . The stock traded as high as A$0.39 ($0.27) and last traded at A$0.38 ($0.27), approximately 126,327 shares traded hands during trading. The stock had previously closed at A$0.37 ($0.26).

The business has a 50-day moving average price of A$0.42. The company has a market capitalization of $81.84 million and a P/E ratio of -9.74. The company has a debt-to-equity ratio of 6.48, a current ratio of 3.83 and a quick ratio of 3.06.

About Medlab Clinical (ASX:MDC)

Medlab Clinical Limited, a medical research and development facility, engages in nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management.

Recommended Story: Bond

Receive News & Ratings for Medlab Clinical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medlab Clinical and related companies with MarketBeat.com's FREE daily email newsletter.